Verona Pharma

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Verona Pharma excels in COPD trials, secures funding for growth

Verona Pharma's strong performance in Phase 3 trials and solid financial position set a positive trajectory for future growth and NDA submission.
While facing competition and addressing various challenges, the company's strategic vision and upcoming milestones offer opportunities for expansion and partnerships.

Verona Pharma reports strong Q1 earnings, gears up for ensifentrine launch

Verona Pharma's Q1 2023 earnings call highlighted strong financial performance, progress towards NDA submission for ensifentrine, and strategic initiatives for the upcoming launch.
Despite facing challenges in managing expenses and navigating regulatory processes, the company remains optimistic about its market positioning and growth prospects.
With a focus on differentiation, global partnerships, and commercial readiness, Verona Pharma is poised for success in the COPD treatment market in 2024 and beyond.
The company's emphasis on marketing, operational setup, and post-ENHANCE data promotion underscores its commitment to maximizing market impact and revenue potential.

Verona Pharma advances ensifentrine with strong Q2 performance and global expansion prospects

Verona Pharma's Q2 2023 performance showcased progress on ensifentrine and a strong financial position, despite a net loss driven by ongoing expenses.
Strengths include positive trial results, a robust cash position, and global expansion efforts, while challenges lie in financial management and regulatory uncertainties.
Opportunities abound in FDA approval prospects, market expansion through subgroup usage, reimbursement optimization, and product portfolio expansion.
Analysts' inquiries highlighted key concerns and strategic considerations for Verona Pharma's future growth and commercial success in the COPD treatment market.

Verona Pharma advances towards FDA approval with strong financials

Verona Pharma progresses towards FDA approval for ensifentrine, with a set action date.
Financially stable with cash reserves and plans for a robust sales force.
Balancing R&D investments with increased expenses and strategic challenges.
Positioned for growth with pipeline expansion and positive data on treatment impact.

Verona Pharma excels in Q4, eyes FDA approval for ensifentrine

Verona Pharma's Q4 2023 earnings call highlighted strong financials, progress with ensifentrine's FDA submission, and strategic plans for commercial launch and market positioning. While facing challenges in FDA review and commercial strategy, the company remains optimistic about ensifentrine's market prospects and growth opportunities.

Verona Pharma excels in Q1 with ensifentrine progress and financial strength

Verona Pharma's Q1 2024 performance highlighted progress on ensifentrine, strong commercial launch preparations, and a robust financial position.
Strengths lie in ensifentrine's novelty, disease awareness focus, and the company's solid financial foundation.
Challenges include addressing analyst queries, market competition, and ensuring a successful commercial launch.
Opportunities abound in leveraging ensifentrine's utility, financial strength, and the potential for market disruption in COPD treatment.

Verona Pharma reports strong Ohtuvayre sales but faces challenges

Verona Pharma's Q3 2024 earnings call highlighted strong net product sales for Ohtuvayre, but also revealed a net loss after tax. The company's successful launch of Ohtuvayre and progress in new trials and partnerships demonstrate potential for growth. However, Verona Pharma faces challenges in addressing various aspects of its business and potential competition in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

US FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference call today at 9:00 a.m. EDT / 1:00 p.m.

Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the third quarter ended September 30, 2023 on Thursday, November 2, 2023 and host an investment community conference call at 9:00 a.m. EDT / 1:00 p.m. GMT to discuss these financial results and provide a corporate update.

Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Verona Pharma PLC American Depositary Share (VRNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Verona Pharma PLC American Depositary Share (VRNA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it will hold an Investor Update in New York City for investors and analysts on Wednesday, October 18, 2023, from 8:00 - 10:00 AM ET.

Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023

Verona Pharma PLC American Depositary Share (VRNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -21.27% in 4 Weeks, Here's Why Verona Pharma PLC American Depositary Share (VRNA) Looks Ripe for a Turnaround

PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine,  an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces four presentations on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at CHEST Annual Meeting (“CHEST”) 2023.

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

PDUFA Target Action Date of June 26, 2024

Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

Substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 Substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

Verona Pharma has submitted a New Drug Application (NDA) for ensifentrine, a potential treatment for COPD, to the FDA. The FDA has a 60-day window to accept or reject the filing, with a potential approval date as early as January 2024. Verona Pharma's commercial strategy includes a swift launch in 1H24, building a sales team, and planning an EU launch by late 2024.

Verona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming Soon

LONDON and RALEIGH, N.C., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces effective September 1, 2023, Ms. Christina Ackermann will join the board as a Non-Executive Director.

Christina Ackermann Joins Verona Pharma as Non-Executive Director

Verona Pharma is seeking FDA approval for its COPD treatment, ensifentrine, in 2024. The company has a strong financial position with substantial cash reserves and no immediate need for additional financing. Verona Pharma's ensifentrine has the potential to disrupt the COPD treatment paradigm and carve a niche for itself in the market.

Verona Pharma: Financial Health And COPD Market Impact 2024

Verona Pharma plc is a London-based biopharma company focused on developing respiratory disease treatments. The company recently submitted a NDA for its primary drug candidate that is targeting the large and growing COPD market. The stock has risen impressively since late-stage trial results came out late in 2022. However, insiders have been consistently selling shares in 2023.

Verona Pharma: Targeting The Large COPD Market

Verona Pharma plc. (NASDAQ:VRNA ) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants David Zaccardelli - Chief Executive Officer Mark Hahn - Chief Financial Officer Kathy Rickard - Chief Medical Officer Christopher Martin - Senior Vice President of Commercial Conference Call Participants Andreas Argyrides - Wedbush Andrew Tsai - Jefferies Edward Nash - Canaccord Genuity Thomas Shrader - BTIG Boobalan Pachaiyappan - H.C.

Verona Pharma plc. (VRNA) Q2 2023 Earnings Call Transcript

NDA submitted to US FDA for ensifentrine for maintenance treatment of COPD Phase 3 ENHANCE data published in the American Journal of Respiratory and Critical Care Medicine Strong balance sheet to support commercial launch preparations Conference call today at 9:00 a.m. EDT / 2:00 p.m.

Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

LONDON and RALEIGH, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that senior management will present a company overview at the 43rd Annual Canaccord Growth Conference on Wednesday, August 9, 2023 at 12:00 PM EDT / 5:00 PM BST.

Verona Pharma to Present at 43rd Annual Canaccord Growth Conference

LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the second quarter ended June 30, 2023 on Thursday, August 3, 2023 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update

Ensifentrine improved lung function, symptoms and quality of life and reduced exacerbations in data published in high impact peer reviewed journal Ensifentrine improved lung function, symptoms and quality of life and reduced exacerbations in data published in high impact peer reviewed journal

Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine

LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces the submission of a New Drug Application (“NDA”) to the US Food and Drug Administration (“FDA”) for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease (“COPD”).

Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD

Verona Pharma, a clinical-stage biopharmaceutical company, is making strides with its novel COPD treatment, ensifentrine, exhibiting promise in addressing significant unmet needs in the COPD market. The company's Q1 2023 financial report showcases a robust financial standing, with a cash balance of $291.4 million and a net loss reduction from the previous year.

Verona Pharma: Poised For A Breakthrough In COPD Treatment Amidst Favorable Financial Position

LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:00 AM EDT / 1:00 PM BST.

Verona Pharma to Present at Jefferies Healthcare Conference

Verona Pharma plc's Ensifentrine is the first drug that combines bronchodilation and anti-inflammatory effects in COPD. Phase 3 data showed that the drug showed a 40% pooled reduction in the rate of exacerbations compared to the placebo.

Verona Pharma: Revolutionizing COPD With First Triple Mechanism Inhaled Drug

Verona Pharma plc (NASDAQ:VRNA ) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Kathleen Rickard - Chief Medical Officer Christopher Martin - Senior Vice President Commercial Conference Call Participants Andreas Argyrides - Wedbush David Risinger - SVB Securities Thomas Shrader - BTIG Boobalan Pachaiyappan - H.C. Wainwright Joon Lee - Truist Securities Operator Good morning.

Verona Pharma plc (VRNA) Q1 2023 Earnings Call Transcript

NDA submission on schedule for Q2 2023 12 abstracts and one symposium expanding on successful Phase 3 ENHANCE data to be presented at American Thoracic Society 2023 Strong balance sheet to support commercial launch preparations Conference call today at 9:00 a.m. EDT / 2:00 p.m.

Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

12 Abstracts and one Symposium further support potential of ensifentrine, a first-in-class, selective, dual inhibitor of PDE3 and PDE4

Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023

LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

News for Verona Pharma Stock (VRNA)